Compare RLJ & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | NTLA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | N/A | 2016 |
| Metric | RLJ | NTLA |
|---|---|---|
| Price | $8.17 | $13.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $8.58 | ★ $20.45 |
| AVG Volume (30 Days) | 1.8M | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.36 | $73.07 |
| P/E Ratio | $188.67 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $6.16 | $5.90 |
| 52 Week High | $9.58 | $28.24 |
| Indicator | RLJ | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 54.60 |
| Support Level | $6.93 | $10.44 |
| Resistance Level | $8.56 | $14.61 |
| Average True Range (ATR) | 0.31 | 0.96 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 44.77 | 58.72 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.